Medical Condition News

RSS

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

Tobacco policies reduce exposure to secondhand smoke: The Cochrane Library

In countries and states that have introduced policies that restrict smoking in public, people have less exposure to secondhand smoke. There is also a reduction in the number of people who have heart attacks, as well as an improvement in other indicators of health. These findings are reported in a new review published in the April issue of The Cochrane Library.

15 Apr 2010

Gene defect promotes aggressive forms of ovarian cancer

CANCER RESEARCH UK scientists have discovered how mistakes in a key gene drive the early stages of aggressive ovarian cancers. This could improve diagnosis of aggressive forms of the disease and lead to new treatments, according to a study published in the Journal of Pathology this month.

15 Apr 2010

Scientists uncover new genes responsible for cancer, deafness

From deep within the genomes of organisms as diverse as plants, worms and yeast, scientists have uncovered new genes responsible for causing human diseases such as cancer and deafness.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

GBS cases reduce following 2009 H1N1 vaccination: Research study

A new study finds that reports of a neurologic disease called Guillain-Barré syndrome have been low after 2009 H1N1 vaccination, according to a research study that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Pancreatic Cancer Action Network, AACR awarded four Innovative Grants for pancreatic cancer research

The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded four Innovative Grants; three Career Development Awards; one Pathway to Leadership Grant; and one Fellowship Award to outstanding researchers for their innovative research proposals which have the potential to lead to medical breakthroughs in the treatment of pancreatic cancer.

15 Apr 2010

Genomic component playing key role in promoting breast cancer progression discovered

Life Technologies Corporation today announced that its scientists have teamed with researchers from Stanford University School of Medicine, and other institutions to discover a genomic component that plays a key role in promoting breast cancer progression. A study published today in the journal Nature details how levels of a specific kind of non-coding RNA molecule in primary breast tumors regulate metastasis and tumor invasiveness and may be an important target for cancer diagnosis and therapy.

15 Apr 2010

Artificial pancreas system succeeds in maintaining near-normal glucose levels

An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston University.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

15 Apr 2010

Researchers identify new strategy for treating acute myeloid leukemia

Researchers have identified a self-feeding "vicious circle" of molecules that keeps acute leukemia cells alive and growing and that drives the disease forward.

15 Apr 2010

Study combines CT and VBM to provide accurate picture of autistic brain

A new study, the first of its kind, combines two complementary analytical brain imaging techniques, to provide a more comprehensive and accurate picture of the neuroanatomy of the autistic brain. The study, published in the April issue of neuroimaging journal Human Brain Mapping, was conducted by researchers at The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the Universit- de Montr-al.

15 Apr 2010

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.

15 Apr 2010

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

A brain-imaging study published today in the Archives of Neurology suggests that a major genetic risk factor for Alzheimer's disease in the Anglo population is also a risk factor for the disease in Latinos.

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

SNM has been awarded a $48,000 grant from the Agency for Healthcare Research and Quality (AHRQ) to hold a conference to develop research on the comparative effectiveness of positron emission tomography (PET) and other molecular imaging techniques. The primary emphasis will be on the diagnosis and management of cancer patients, but both cardiology and neurology questions will also be addressed.

15 Apr 2010

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

AVANIR Pharmaceuticals, Inc. today announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia™ (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis.

15 Apr 2010

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

A study led by Mayo Clinic suggests remission from Crohn's disease may be more likely if patients get biologic therapy combined with immune-suppressing drugs first instead of immune-suppressing drugs alone. The study, published in the April 15, 2010 issue of the New England Journal of Medicine, found treatment of moderate to severe Crohn's disease with infliximab plus azathioprine allows more patients to achieve remission and mucosal healing than therapy with azathioprine alone.

15 Apr 2010

Medical Condition News

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Tobacco policies reduce exposure to secondhand smoke: The Cochrane Library

Gene defect promotes aggressive forms of ovarian cancer

Scientists uncover new genes responsible for cancer, deafness

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

GBS cases reduce following 2009 H1N1 vaccination: Research study

Pancreatic Cancer Action Network, AACR awarded four Innovative Grants for pancreatic cancer research

Genomic component playing key role in promoting breast cancer progression discovered

Artificial pancreas system succeeds in maintaining near-normal glucose levels

Patients with RLS using rotigotine achieve sustained improvements

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers identify new strategy for treating acute myeloid leukemia

Study combines CT and VBM to provide accurate picture of autistic brain

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Comparing effectiveness of PET and other molecular imaging techniques: SNM receives $48,000 AHRQ grant

Efficacy data from Phase III STAR trial of Zenvia presented at AAN Annual Meeting

Infliximab-azathioprine combination helps more Crohn's disease patients achieve remission

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News